References

akusherstvo

Obstetrics, Gynecology and Reproduction

Акушерство, Гинекология и Репродукция

2313-73472500-3194

IRBIS LLC

10.17749/2313-7347/ob.gyn.rep.2023.406

akusherstvo-1656

Research Article

REVIEW ARTICLES

НАУЧНЫЕ ОБЗОРЫ

Hemostasis parameters as prognostic biomarkers in gynecological cancer patients

Показатели гемостаза как прогностические биомаркеры у онкогинекологических пациенток

https://orcid.org/0000-0001-7441-2778

Слуханчук

Е. В.

Slukhanchuk

E. V.

Слуханчук Екатерина Викторовна – к.м.н., доцент кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Ekaterina V. Slukhanchuk – MD, PhD, Associate Professor, Department of Obstetrics, Gynecology and Perinatal Medicine

Bolshaya Pirogovskaya Str., Moscow 119991

ekaterina@ginekologhirurg.ru

https://orcid.org/0000-0001-8404-1042

Бицадзе

В. О.

Bitsadze

V. O.

Бицадзе Виктория Омаровна – д.м.н., профессор РАН, профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

Scopus Author ID: 6506003478, Researcher ID: F-8409-2017

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health

Scopus Author ID: 6506003478, Researcher ID: F-8409-2017

Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-7456-2386

Солопова

А. Г.

Solopova

A. G.

Солопова Антонина Григорьевна – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

Scopus Author ID: 6505479504, Researcher ID: Q-1385-2015

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Antonina G. Solopova – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine

Scopus Author ID: 6505479504, Researcher ID: Q-1385-2015

Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-0725-9686

Хизроева

Д. Х.

Khizroeva

J. Kh.

Хизроева Джамиля Хизриевна – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

Scopus Author ID: 57194547147, Researcher ID: F-8384-2017

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine

Scopus Author ID: 57194547147

Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-9899-9910

Гри

Ж.-К.

Gris

J.-C.

Гри Жан-Кристоф – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); профессор гематологии, зав. лабораторией гематологии факультета биологических и фармацевтических наук Университета Монпелье и Университетской больницы Нима, Франция; иностранный член РАН

Scopus Author ID: 7005114260, Researcher ID: AAA-2923-2019

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Франция, 34090 Монпелье, ул. Огюста Бруссоне, д. 163

Jean-Christophe Gris – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health, Sechenov University; Professor of Haematology, Head of the Laboratory of Haematology, Faculty of Biological and Pharmaceutical Sciences; Foreign Member of RAS

Scopus Author ID: 700511426, Researcher ID: AAA-2923-2019

Bolshaya Pirogovskaya Str., Moscow 119991

63 Rue Auguste Broussonnet, Montpellier 34090

https://orcid.org/0000-0002-9576-1368

Элалами

И.

Elalamy

Элалами Исмаил – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); профессор медицинского Университета Сорбонны, Париж, Франция; директор гематологии Центра Тромбозов, Госпиталь Тенон, Париж, Франция

Scopus Author ID: 7003652413, Researcher ID: AAC-9695-2019

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

75006 Париж, Улица медицинского факультета, д. 12

75020 Париж, Китайская улица, д. 4

Ismail Elalamy – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health, Sechenov University; Professor, Medicine Sorbonne University; Director of Hematology, Department of Thrombosis Center, Hospital Tenon

Scopus Author ID: 7003652413, Researcher ID: AAC-9695-2019

Bolshaya Pirogovskaya Str., Moscow 119991

2 Rue de l’École de Médecine, Paris 75006

4 Rue de la Chine, Paris 75020

https://orcid.org/0000-0003-0226-9276

Щербаков

Д. В.

Shcherbakov

D. V.

Щербаков Денис Викторович – к.м.н., доцент кафедры общей гигиены института общественного здоровья имени Ф.Ф. Эрисмана

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Denis V. Shcherbakov – MD, PhD, Associate Professor, Department of General Hygiene

Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-9783-1796

Шкода

А. С.

Shkoda

A. S.

Шкода Андрей Сергеевич – д.м.н., профессор, главный врач ГБУЗ «Городская клиническая больница No 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»

123423 Москва, ул. Саляма Адиля, д. 2/44

Andrey S. Shkoda – MD, Dr Sci Med, Professor, Chief Physician

2/44 Salyama Adilya Str., Moscow 123423

https://orcid.org/0000-0002-1339-4155

Панкратьева

Л. Л.

Pankratyeva

L. L.

Панкратьева Людмила Леонидовна – д.м.н., врач-неонатолог, врач-гематолог, руководитель научно-клинического центра ГБУЗ «Городская клиническая больница No 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»; доцент, профессор кафедры педиатрии и организации здравоохранения ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Министерства здравоохранения Российской Федерации

Scopus Author ID: 7006391091, Author ID: 697284

123423 Москва, ул. Саляма Адиля, д. 2/44

117997 Москва, ул. Саморы Машела, д. 1

Liudmila L. Pankratyeva – MD, Dr Sci Med, Neonatologist, Hematologist, Head of the Clinical Research Center, Vorokhobov City Clinical Hospital No 67; Associate Professor, Professor, Department of Pediatrics and Health Organization, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Scopus Author ID: 7006391091, Author ID: 697284

2/44 Salyama Adilya Str., Moscow 123423

1 Samora Machel Str., Moscow 117997

https://orcid.org/0000-0002-3337-4995

Унгиадзе

Д. Ю.

Ungiadze

J. Yu.

Унгиадзе Джумбер Юрьевич – д.м.н., профессор медицинского факультета

6010 Батуми, ул. Ниношвили, д. 35

Jumber Yu. Ungiadze – MD, Dr Sci Med, Professor, Faculty of Medicine

35 Ninoshvili Str., Batumi 6010

https://orcid.org/0000-0001-6396-4948

Ашрафян

Л. А.

Ashrafyan

L. A.

Ашрафян Лев Андреевич – д.м.н., профессор, академик РАН, заслуженный врач РФ, директор Института онкогинекологии и маммологии, зам. директора ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской Федерации

Scopus Author ID: 57194173388

117997 Москва, ул. академика Опарина, д. 4

Levon A. Ashrafyan – MD, Dr Sci Med, Professor, Academician of RAS, Honored Doctor of RF, Head of the Institute of Oncogynecology and Mammology, Deputy Director of Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

4 Akademika Oparina Str., Moscow 117997

Scopus Author ID: 57194173388

https://orcid.org/0000-0001-7415-4633

Макацария

А. Д.

Makatsariya

A. D.

Макацария Александр Давидович – д.м.н., профессор, академик РАН, зав. кафедрой акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); вице-президент Российского общества акушеров-гинекологов (РОАГ); Заслуженный врач Российской Федерации; Почетный профессор Венского Университета

Scopus Author ID: 57222220144, Researcher ID: M-5660-2016

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health, Sechenov University; Vice-President of the Russian Society of Obstetrican-Gynecologists (RSOG); Honorary Doctor of the Russian Federation; Emeritus Professor of the University of Vienna

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияFilatov Clinical Institute of Children's Health, Sechenov UniversityRussian Federation

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Университет МонпельеФранцияFilatov Clinical Institute of Children’s Health, Sechenov University; Montpellier University and University Hospital of NîmesFrance

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Медицинский Университет Сорбонны; Госпиталь ТенонФранцияFilatov Clinical Institute of Children’s Health, Sechenov University; Medicine Sorbonne University; Hospital TenonFrance

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияErisman Institute of Public Health, Sechenov UniversityRussian Federation

ГБУЗ «Городская клиническая больница No 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»РоссияVorokhobov City Clinical Hospital No 67Russian Federation

ГБУЗ «Городская клиническая больница No 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»; ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Министерства здравоохранения Российской ФедерацииРоссияVorokhobov City Clinical Hospital No 67; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation

Батумский государственный университет имени Шота РуставелиГрузияBatumi Shota Rustaveli State UniversityGeorgia

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской ФедерацииРоссияKulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologyRussian Federation

2023

22052023

172257268

2023

Слуханчук Е.В., Бицадзе В.О., Солопова А.Г., Хизроева Д.Х., Гри Ж., Элалами И., Щербаков Д.В., Шкода А.С., Панкратьева Л.Л., Унгиадзе Д.Ю., Ашрафян Л.А., Макацария А.Д.

Slukhanchuk E.V., Bitsadze V.O., Solopova A.G., Khizroeva J.K., Gris J., Elalamy I., Shcherbakov D.V., Shkoda A.S., Pankratyeva L.L., Ungiadze J.Y., Ashrafyan L.A., Makatsariya A.D.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.gynecology.su/jour/article/view/1656

Hypercoagulation is a typical condition for cancer patients. In addition, various arms of the hemostasis system become involved in tumor growth, invasion, metastasis, neoangiogenesis as well as immunoevasion. The magnitude of activated hemostasis is driven by tumor phenotype. Parameters characterizing coagulation, intensity of fibrinolysis processes, platelet aggregation and activation as well as endothelial activation mirror magnitude of hemostasis activation in oncological process, but may also be considered as candidate markers of tumor progression and predictors of oncological diseases outcome. This review summarizes the study data assessing a value of predictive hemostasis biomarkers for overall survival and response to therapy in oncogynecology and mammology. The most promising biomarkers have been identified and used in the future for risk stratification as well as personalized patient management.

Гиперкоагуляция характерна для онкологических пациентов. Помимо этого, различные звенья системы гемостаза принимают участие в росте опухоли, инвазии, метастазировании, неоангиогенезе и уклонении от иммунного контроля. Выраженность активации системы гемостаза зависит от фенотипа опухоли. Показатели, характеризующие коагуляцию, интенсивность процессов фибринолиза, агрегацию и активацию тромбоцитов, а также активацию эндотелия отражают выраженность активации гемостаза на фоне онкологического процесса, но могут стать и кандидатами в маркеры прогрессии опухоли и прогнозирования исходов у онкологических пациенток. В данном обзоре обобщены данные исследований, в которых изучалась прогностическая ценность биомаркеров гемостаза в отношении общей выживаемости и ответа на терапию в онкогинекологии и маммологии. Выделены наиболее многообещающие биомаркеры, которые могут быть использованы для стратификации риска и персонализированного ведения пациентов в будущем.

гемостазбиомаркерыраквыживаемостьпрогрессирование

hemostasisbiomarkerscancersurvivalprogression

References1

Hisada Y., Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506. https://doi.org/10.1182/blood-2017-03-743211.

Mulder F.I., Horvàth-Puhó E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69. https://doi.org/10.1182/blood.2020007338.

Moik F., Ay C., Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res. 2020;191 Suppl 1:S3–S11. https://doi.org/10.1016/S0049-3848(20)30389-3.

Khorana A.A., Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. https://doi.org/10.1038/s41572-022-00336-y.

Chew H.K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64. https://doi.org/10.1001/archinte.166.4.458.

Riedl J.M., Schwarzenbacher E., Moik F. et al. Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel. Thromb Haemost. 2022;122(4):633–45. https://doi.org/10.1055/a-1548-4847.

Moik F., Chan W.-S.E., Wiedemann S. et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669–78. https://doi.org/10.1182/blood.2020007878.

Elyamany G., Alzahrani A.M., Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129–37. https://doi.org/10.4137/CMO.S18991.

Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. https://doi.org/10.1007/s11239-015-1311-6.

Laporte S., Mismetti P., Décousus H. et al. Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 2008;117(13):1711–6. https://doi.org/10.1161/CIRCULATIONAHA.107.726232.

Puurunen M.K., Gona P.N., Larson M.G. et al. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res. 2016;145:27–33. https://doi.org/10.1016/j.thromres.2016.06.033.

Khorana A., Francis C., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.

Blann A.D., Lip G.Y. Venous thromboembolism. BMJ. 2006;332(7535):215–9. https://doi.org/10.1136/bmj.332.7535.215.

Blann A.D., Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740. https://doi.org/10.4061/2011/394740.

Ades S., Kumar S., Alam M. et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. J Thromb Haemost. 2015;13(6):998–1003. https://doi.org/10.1111/jth.12910.

Corrales-Rodriguez L., Soulières D., Weng X. et al. Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study. Thromb Res. 2014;133(1):48–51. https://doi.org/10.1016/j.thromres.2013.10.042.

Nielsen C., Birgens H.S., Nordestgaard B.G. et al. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96(3):450–3. https://doi.org/10.3324/haematol.2010.033191.

Shetty S., Kulkarni B., Pai N. et al. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134(1):82–5. https://doi.org/10.1309/AJCP7VO4HAIZYATP.

Regina S., Valentin J.-B., Lachot S. et al. Increased tissue factor expression is associated with reduced survival in non–small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55(10):1834–42. https://doi.org/10.1373/clinchem.2009.123695.

Ribeiro F.S., Simao T.A., Amoêdo N.D. et al. Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncol Rep. 2009;21(6):1599–604. https://doi.org/10.3892/or_00000393.

van den Berg Y.W., Osanto S., Reitsma P.H., Versteeg H.H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119(4):924–32. https://doi.org/10.1182/blood-2011-06-317685.

Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2(2):209–15. https://doi.org/10.1038/nm0296-209.

Vrana J.A., Stang M.T., Grande J.P., Getz M.J. Expression of tissue factor in tumor stroma correlates with progression to Invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor β family. Cancer Res. 1996;56(21):5063–70.

Hell L., Däullary T., Burghart V. et al. Extracellular vesicle-associated tissue factor activity in prostate cancer patients with disseminated intravascular coagulation. Cancers (Basel). 2021;13(7):1487. https://doi.org/10.3390/cancers13071487.

Hisada Y., Garratt K.B., Maqsood A. et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Adv. 2021;5(2):487–95. https://doi.org/10.1182/bloodadvances.2020003149.

Adams G.N., Rosenfeldt L., Frederick M. et al. Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Cancer Res. 2015;75(19):4235–43. https://doi.org/10.1158/0008-5472.CAN-15-0964.

Wojtukiewicz M.Z., Hempel D., Sierko E. et al. Protease-activated receptors (PARs) – biology and role in cancer invasion and metastasis. Cancer Metastasis Rev. 2015;34(4):775–96. https://doi.org/10.1007/s10555-015-9599-4.

Liu Y., Jiang P., Capkova K. et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target. Cancer Res. 2011;71(20):6492–502. https://doi.org/10.1158/0008-5472.CAN-11-1145.

Franco A.T., Corken A., Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–8. https://doi.org/10.1182/blood-2014-08-531582.

Roweth H.G., Battinelli E.M. Lessons to learn from tumor-educated platelets. Blood. 2021;137(23):3174–80. https://doi.org/10.1182/blood.2019003976.

Stegner D., Dütting S., Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133 Suppl 2:S149–57. https://doi.org/10.1016/S0049-3848(14)50025-4.

Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. https://doi.org/10.1016/j.ccr.2011.09.009.

Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34. https://doi.org/10.1038/nrc3004.

Nazari P.M.S., Marosi C., Moik F. et al. Low systemic levels of chemokine CC motif ligand 3 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma. Cancers (Basel). 2019;11(12):2020. https://doi.org/10.3390/cancers11122020.

Hisada Y., Grover S.P., Maqsood A. et al. Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica. 2020;105(1):218–25. https://doi.org/10.3324/haematol.2019.217083.

Moik F., Zöchbauer-Müller S., Posch F. et al. Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer. Cancers (Basel). 2020;12(6):1619. https://doi.org/10.3390/cancers12061619.

Marchetti M., Falanga A. Hemostatic biomarkers in occult cancer and cancer risk prediction. Thromb Res. 2020;191 Suppl 1:S37–S42. https://doi.org/10.1016/S0049-3848(20)30395-9.

Olson J.D. D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem. 2015;69:1–46. https://doi.org/10.1016/bs.acc.2014.12.001.

Wells P.S., Anderson D.R., Rodger M. et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–35. https://doi.org/10.1056/NEJMoa023153.

Di Nisio M., Squizzato A., Rutjes A.W. et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost. 2007;5(2):296–304. https://doi.org/10.1111/j.1538-7836.2007.02328.x.

Weber T., Ho S., Auer J. et al. D-dimer in acute aortic dissection. Chest. 2003;123(5):1375–8. https://doi.org/10.1378/chest.123.5.1375.

Lehman C.M., Wilson L.W., Rodgers G.M. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122(2):178–84. https://doi.org/10.1309/X4YN-001G-U51N-GG9Y.

Ay C., Dunkler D., Pirker R. et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97(8):1158–64. https://doi.org/10.3324/haematol.2011.054718.

Li W., Tang Y., Song Y. et al. Prognostic role of pretreatment plasma D-dimer in patients with solid tumors: a systematic review and metaanalysis. Cell Physiol Biochem. 2018;45:1663–76. https://doi.org/10.1159/000487734.

Wu J., Fu Z., Liu G. et al. Clinical significance of plasma D-dimer in ovarian cancer: a meta-analysis. Medicine (Baltimore). 2017;96(25):e7062. https://doi.org/10.1097/MD.0000000000007062.

Lin Y., Liu Z., Qiu Y. et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(10):1494–503. https://doi.org/10.1016/j.ejso.2018.07.052.

Moik F., Posch F., Grilz E. et al. Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Thromb Res. 2020;187:9–17. https://doi.org/10.1016/j.thromres.2020.01.002.

Perisanidis C., Psyrri A., Cohen E. et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–70. https://doi.org/10.1016/j.ctrv.2015.10.002.

Asada Y., Sumiyoshi A., Hayashi T. et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38(5):469–9. https://doi.org/10.1016/0049-3848(85)90180-x.

Goertz L., Schneider S.W., Desch A. et al. Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget. 2016;7(42):68527–45. https://doi.org/10.18632/oncotarget.11832.

Bauer A.T., Suckau J., Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153–63. https://doi.org/10.1182/blood-2014-08-595686.

Chauhan A.K., Motto D.G., Lamb C.B. et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767–76. https://doi.org/10.1084/jem.20051732.

Bergmeier W., Chauhan A.K., Wagner D.D. Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99(2):264–70. https://doi.org/10.1160/TH07-10-0638.

De Meyer S.F., Savchenko A.S., Haas M.S. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood. 2012;120(26):5217–223. https://doi.org/10.1182/blood-2012-06-439935.

Blann A.D., Balakrishnan B., Shantsila E. et al. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate. 2011;71(10):1047–53. https://doi.org/10.1002/pros.21319.

Pépin M., Kleinjan A., Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016;14(2):306–15. https://doi.org/10.1111/jth.13205.

Bittar L.F., de Paula E.V., Mello T.B. et al. Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17(5):514–8. https://doi.org/10.1177/1076029610375815.

Obermeier H.L., Riedl J., Ay C. et al. The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost. 2019;3(3):503–14. https://doi.org/10.1002/rth2.12197.

Moik F., Prager G., Thaler J. et al. Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer. Arterioscler Thromb Vasc Biol. 2021;41(11):2837–47. https://doi.org/10.1161/ATVBAHA.121.316463.

Beer J., Haeberli A., Vogt A. et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88(8):745–49.

Giaccherini C., Marchetti M., Masci G. et al. Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica. 2020;105(6):1704–11. https://doi.org/10.3324/haematol.2019.228981.

Kuhn W., Schmalfeldt B., Reuning U. et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999;79(11–12):1746–51. https://doi.org/10.1038/sj.bjc.6690278.

Schmalfeldt B., Kuhn W., Reuning U. et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995;55(48):3958–63.

Schmitt M., Harbeck N., Thomssen C. et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997;78(1):285–96.

Bharadwaj A.G., Holloway R.W., Miller V.A., Waisman D.V. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers (Basel). 2021;13(8):1838. https://doi.org/10.3390/cancers13081838.

Duffy M.J. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans. 2002;30(2):207–10.

Harbeck N., Kates R.E., Look M.P. et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002;62(16):4617–22.

Levi M., de Jonge E., van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36(1):41–9. https://doi.org/10.1080/07853890310017251.

Griffin J.H., Zlokovic B., Fernández J.A. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol. 2002;39(3):197–205. https://doi.org/10.1053/shem.2002.34093.

Castoldi E., Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8(3):445–53. https://doi.org/10.1111/j.1538-7836.2009.03711.x.

Sarig G., Michaeli Y., Lanir N., Brenner B., Haim N. Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost. 2005;3(3):589–90. https://doi.org/10.1111/j.1538-7836.2005.01168.x.

Wilts I., Hutten B., Meijers J. et al. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thromb Res. 2017;154:1–6. https://doi.org/10.1016/j.thromres.2017.03.001.

Ferroni P., Roselli M., Martini F. et al. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer. 2004;111(3):404–8. https://doi.org/10.1002/ijc.20189.

Kanz R., Vukovich T., Vormittag R. et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2011;9(1):57–63. https://doi.org/10.1111/j.1538-7836.2010.04069.x.

Reitter E.M., Kaider A., Ay C. et al. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. J Thromb Haemost. 2016;14(2):294–305. https://doi.org/10.1111/jth.13218.

Man Y.-N., Wang Y.-.N, Hao J. et al. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer. 2015;25(1):24–32. https://doi.org/10.1097/IGC.0000000000000303.

Mirshahi S., Pujade-Lauraine E., Soria C. et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti-cancer treatment. Cancer. 1992;69(9):2289–92. https://doi.org/10.1002/1097-0142(19920501)69:9<2289::aid-cncr2820690914>3.0.co;2-a.

Li Q., Cong R., Kong F. et al. Fibrinogen is a coagulation marker associated with the prognosis of endometrial cancer. Onco Targets Ther. 2019;12:9947–56. https://doi.org/10.2147/OTT.S222813.

Seebacher V., Polterauer S., Grimm C. et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952–6. https://doi.org/10.1038/sj.bjc.6605547.

Nakamura K., Nakayama K., Ishikawa M. et al. High pre-treatment plasma D-dimer level as a potential prognostic biomarker for cervical carcinoma. Anticancer Res. 2016;36(6):2933–38.

Lal I., Dittus K., Holmes C.E. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 2013;15(4):1–11. https://doi.org/10.1186/bcr3425.

Blackwell K., Haroon Z., Broadwater G. et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18(3):600–8. https://doi.org/10.1200/JCO.2000.18.3.600.

Mandoj C., Pizzuti L., Sergi D. et al. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. J Transl Med. 2018;16(1):1–9. https://doi.org/10.1186/s12967-018-1511-x.

Dirix L.Y., Salgado R., Weytjens R. et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86(3):389–95. https://doi.org/10.1038/sj.bjc.6600069.

Liu Y.-L., Lu Q., Liang J.-W. et al. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer. Medicine (Baltimore). 2015;94(9):e481. https://doi.org/10.1097/MD.0000000000000481.

Falanga A., Santoro A., Labianca R. et al. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thromb Res. 2016;140 Suppl 1:S55–9. https://doi.org/10.1016/S0049-3848(16)30099-8.

Marchetti M., Giaccherini C., Masci G. et al. Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemost. 2020;18(9):2220–31. https://doi.org/10.1111/jth.14891.

Tinholt M., Vollan H.K.M., Sahlberg K.K. et al. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Res. 2015;17(1):44. https://doi.org/10.1186/s13058-015-0548-5.

Xu C., Wang H., He H. et al. Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC Cancer. 2013;13:118. https://doi.org/10.1186/1471-2407-13-118.

Henry N.L., Hayes D.F. Cancer biomarkers. Mol Oncol. 2012;6(2):140–6. https://doi.org/10.1016/j.molonc.2012.01.010.

The authors declare that there are no conflicts of interest present.